Are Analysts Bullish about Celgene Corporation (NASDAQ:CELG) after last week?

Celgene Corporation (NASDAQ:CELG) Logo
Investors sentiment decreased to 0.55 in 2019 Q2. Its down 0.21, from 0.76 in 2019Q1. It turned negative, as 97 investors sold Celgene Corporation shares while 443 reduced holdings. 83 funds opened positions while 216 raised stakes. 466.35 million shares or 3.39% less from 482.72 million shares in 2019Q1 were reported.
Private Trust Na invested in 4,849 shares or 0.09% of the stock. Global Endowment Mngmt Limited Partnership accumulated 5,590 shares. Intrust Commercial Bank Na, Kansas-based fund reported 8,016 shares. Tocqueville Asset Ltd Partnership reported 45,909 shares. Moreover, Smith Howard Wealth Mgmt Lc has 0.65% invested in Celgene Corporation (NASDAQ:CELG) for 16,540 shares. The Pennsylvania-based Mycio Wealth Partners Ltd Co has invested 0.12% in Celgene Corporation (NASDAQ:CELG). Fcg Advsr owns 5.25% invested in Celgene Corporation (NASDAQ:CELG) for 180,085 shares. Sandy Spring Bancorp reported 2,910 shares. Ipswich Invest Mngmt Incorporated owns 5,120 shares for 0.15% of their portfolio. Mutual Of America Management Llc invested 0.17% in Celgene Corporation (NASDAQ:CELG). Patten And Patten Inc Tn has invested 0.15% of its portfolio in Celgene Corporation (NASDAQ:CELG). Sigma Planning Corporation has invested 0.04% in Celgene Corporation (NASDAQ:CELG). Gardner Lewis Asset Management L P holds 413,168 shares. Indiana Tru & Investment Mgmt has invested 0.62% in Celgene Corporation (NASDAQ:CELG). Private Harbour Inv Mgmt Counsel Ltd Liability Corp invested in 22,857 shares or 2.18% of the stock.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 2 analysts covering Celgene (NASDAQ:CELG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Celgene has $103 highest and $100 lowest target. $101.50’s average target is 3.22% above currents $98.33 stock price. Celgene had 10 analyst reports since March 26, 2019 according to SRatingsIntel. Mizuho maintained the stock with “Buy” rating in Monday, June 24 report. The company was maintained on Monday, June 24 by Cantor Fitzgerald. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

24/06/2019 Broker: Mizuho Rating: Buy New Target: $103 Maintain
24/06/2019 Broker: Cantor Fitzgerald Rating: Hold New Target: $100 Maintain
03/05/2019 Broker: BidaskScore Rating: Hold Upgrade
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/04/2019 Broker: BidaskScore Rating: Sell Downgrade
05/04/2019 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
01/04/2019 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Downgrade
01/04/2019 Broker: UBS Old Rating: Buy New Rating: Neutral Downgrade
01/04/2019 Broker: Atlantic Securities Old Rating: Overweight New Rating: Neutral Downgrade
26/03/2019 Broker: Canaccord Genuity Rating: Hold Maintain

The stock decreased 0.30% or $0.3 during the last trading session, reaching $98.33. About 2.03M shares traded. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since September 13, 2018 and is uptrending. It has outperformed by 3.32% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $69.69 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 13.44 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: 247Wallst.com which released: “Major Biotechs Scare Off Short Sellers – 24/7 Wall St.” on September 12, 2019, also Finance.Yahoo.com with their article: “Seth Klarman Buys XPO Logistics, Exits 3 Positions in 2nd Quarter – Yahoo Finance” published on August 14, 2019, Finance.Yahoo.com published: “3 Cancer Treatment Stocks to Buy Right Now – Yahoo Finance” on August 25, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight – Benzinga” published on September 02, 2019 as well as Seekingalpha.com‘s news article titled: “Merger Arbitrage Mondays – Liberty Tax Agrees To Pay 44% More For Sears Hometown And Outlet Stores – Seeking Alpha” with publication date: September 02, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.